Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

Benzinga · 1d ago
Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.